More recently, KV1.3 has been investigated as a target for inflammation in the central nervous system where KV1.3 expression has been described on activated, “M1-like” or disease-associated microglia in human brain or in rodent models of Alzheimer’s disease (Maezawa et al., 2018; Ramesha et al., 2021), multiple sclerosis (Rus et al., 2005), Parkinson’s disease (Sarkar et al., 2020), and ischemic stroke (Chen et al., 2018). This evidence concerns the gene KCNA3 and Parkinson disease.